Cardiovascular Diseases
255 treatments and conditions followed through the public trial records. Not medical advice. How a status is set
Lists the pairs whose condition is this category or one beneath it. A category is not a diagnosis and not advice.
Narrower: Acute Coronary Syndrome 12, Aneurysm 1, Angina Pectoris 9, Angina, Stable 3, Angina, Unstable 1, Anterior Wall Myocardial Infarction 1, Arrhythmias, Cardiac 10, Arterial Occlusive Diseases 46, Arteriosclerosis 45, Arteriovenous Malformations 1, Atherosclerosis 20, Atrial Fibrillation 7, Cardiomyopathies 8, Cardiomyopathy, Dilated 1, Cardiomyopathy, Hypertrophic 2, Coronary Artery Disease 24, Coronary Disease 28, Coronary Stenosis 1, Ductus Arteriosus, Patent 2, Embolism 1, Essential Hypertension 1, Heart Arrest 3, Heart Defects, Congenital 3, Heart Diseases 170, Heart Failure 40, Heart Failure, Diastolic 1, Heart Failure, Systolic 3, Hyperemia 1, Hypertension 28, Hypertrophy, Left Ventricular 1, Hypotension 1, Intermittent Claudication 2, Klippel-Trenaunay-Weber Syndrome 1, Microvascular Angina 2, Mitral Valve Insufficiency 1, Mitral Valve Prolapse 1, Myocardial Infarction 27, Myocardial Reperfusion Injury 1, Myocarditis 1, Non-ST Elevated Myocardial Infarction 5, Pericarditis 1, Peripheral Arterial Disease 4, Prehypertension 3, Reperfusion Injury 2, Shock, Cardiogenic 1, ST Elevation Myocardial Infarction 10, Tachycardia, Ventricular 1, Telangiectasia, Hereditary Hemorrhagic 2, Thrombosis 3, Tricuspid Valve Insufficiency 22, Vascular Malformations 4, Vasculitis 2, Venous Thromboembolism 3, Ventricular Dysfunction, Right 2, Ventricular Fibrillation 1
Treatments and conditions
| Treatment and condition | Where it stands | Trials |
|---|---|---|
| "Trained Eye" (Angiography-Guided) LM PCI for coronary artery disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| 1 Stent for coronary artery disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| 2 Stents for coronary artery disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Acetylcysteine for st elevation myocardial infarction | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Amiodarone for heart arrest | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Amrecibart for atrial fibrillation | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Amrecibart for thrombosis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Amrecibart for venous thromboembolism | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Apixaban for heart failure | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Apixaban for thrombosis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Arm 1: treatment with Shockwave Reducer for angina pectoris | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Aroxxen for coronary artery disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Atorvastatin for myocardial infarction | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Autoinjector + EVOLOCUMAB for coronary artery disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Avacopan for vasculitis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Baxdrostat for hypertension | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| BiOSS LIM C for coronary artery disease | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| BiOSS LIM C for coronary stenosis | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| BiVACOR TAH System for heart failure | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Bread with added beta-glucans for hypertension | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CagriSema for hypertension | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Calf Plantar flexion + Dietary nitrate for peripheral arterial disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Canakinumab for atherosclerosis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Canakinumab for myocardial infarction | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cardiovalve TR valve replacement System for tricuspid valve insufficiency | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cardiovascular Polypill for myocardial infarction | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cardiovascular Polypill (Valsartan, Atorvastatin, Aspirin) + Colchicine 0.5 mg for atherosclerosis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cardiovascular Polypill (Valsartan, Atorvastatin, Aspirin) + Colchicine-placebo 0.5 mg for atherosclerosis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Carvedilol for heart failure | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cenvacibart for atrial fibrillation | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Cenvacibart for thrombosis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Cenvacibart for venous thromboembolism | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cholecalciferol for myocardial infarction | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Clazakizumab for atherosclerosis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Clazakizumab for hypertension | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Clopidogrel for acute coronary syndrome | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Clopidogrel for angina, stable | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Clopidogrel for myocardial infarction | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Colchicine for acute coronary syndrome | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Colchicine for coronary artery disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Colchicine for coronary disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Colchicine for heart failure | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Colchicine for myocardial infarction | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Colchicine for myocarditis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Colchicine 0.5 mg for atherosclerosis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Colchicine 0.5 mg for coronary disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Colchicine 0.5 mg for heart diseases | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Colchicine 0.5 mg + Usual Care Group for atherosclerosis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Colchicine-placebo 0.5 mg + Usual Care Group for atherosclerosis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Combined antioxidant therapy for myocardial reperfusion injury | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Combined antioxidant therapy for st elevation myocardial infarction | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Control for hypertension | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Coronary Sinus Reducer for angina pectoris | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Coronary Sinus Reducer for angina, stable | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Coronary Sinus Reducer for coronary artery disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Coronary Sinus Reducer for microvascular angina | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Dapagliflozin for heart failure | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Dapagliflozin + Empagliflozin for heart failure, systolic | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Dapagliflozin propanediol for heart failure, systolic | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| DCD Heart Transplantation Using NRP for heart failure | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| DIAG723 for telangiectasia, hereditary hemorrhagic | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Direct oral anticoagulant for acute coronary syndrome | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Direct oral anticoagulant for embolism | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Direct oral anticoagulant for heart failure | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Direct oral anticoagulant for st elevation myocardial infarction | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| EA-230 90mg/kg/hour for coronary artery disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Echocardiography + Electrocardiogram (ECG) + DEFERIPRONE + Deferoxamine + Deferasirox for arrhythmias, cardiac | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Echocardiography + Electrocardiogram (ECG) + DEFERIPRONE + Deferoxamine + Deferasirox for cardiomyopathies | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| EDG-15400 25 mg for heart failure | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| EDG-15400 50 mg for heart failure | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Edwards EVOQUE System for heart failure | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Edwards EVOQUE System for tricuspid valve insufficiency | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Edwards EWJ-202 Transcatheter Tricuspid Valve Replacement System for tricuspid valve insufficiency | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Electronic Cigarette and behavioural change support. for cardiovascular diseases | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Eloralintide for cardiovascular diseases | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Empagliflozin for cardiomyopathy, hypertrophic | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Empagliflozin for heart defects, congenital | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Empagliflozin for heart failure | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 13 |
| Empagliflozin for heart failure, diastolic | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Empagliflozin for ventricular dysfunction, right | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Enavogliflozin for tricuspid valve insufficiency | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Endocalyx Pro for hypertension | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ENDS (Vaporizer/e-cig) and smoking cessation counseling for cardiovascular diseases | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Enlicitide Decanoate for arteriosclerosis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Essential Pro Paclitaxel Drug-Eluting Balloon for coronary artery disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Evolocumab for coronary artery disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Evolocumab for coronary disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Evolocumab for non-st elevated myocardial infarction | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Evolocumab for st elevation myocardial infarction | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Exercise for hypertension | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Exploratory test group for hypertension | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ferric derisomaltose for heart failure | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Finerenone for atrial fibrillation | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fisetin for intermittent claudication | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fixed-Dose Combination Strategy for hypertension | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Flecainide for heart arrest | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Flecainide for mitral valve prolapse | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Food Security Screening & Referral Program for cardiovascular diseases | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Genicular artery embolization (GAE) for arterial occlusive diseases | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Goflikicept for pericarditis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Heart to Heart Yoga for heart failure | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| HiCM-188 therapy for heart failure | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| High dose CABG/LVAD+iPSC-CMs for heart failure | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| High dose Jia Shen Tablet for heart failure | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| High Dose LX2006 + Low dose LX2006 + Mid Dose LX2006 for cardiomyopathies | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| High-resistance inspiratory muscle strength training for hypertension | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| hiPSC-CM therapy for cardiomyopathy, dilated | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| hiPSC-CM therapy for heart failure | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Hyperpolarized 13C-pyruvate for heart failure | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| IBI3016 for hypertension | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ibuprofen for ductus arteriosus, patent | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| iCM012 solution 2 mg/mL for reperfusion injury | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ime for hypertension | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ime for prehypertension | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Impella 5.5 for shock, cardiogenic | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Inclisiran for acute coronary syndrome | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Inclisiran for non-st elevated myocardial infarction | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Inclisiran for st elevation myocardial infarction | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Infliximab for aneurysm | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Infliximab for vasculitis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Innoventric Unica™ System for tricuspid valve insufficiency | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Inspiratory muscle strength training for hypertension | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Inspiratory muscle strength training for prehypertension | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Inspiratory muscle training (IMT) for hypertension | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Intensified medical follow-up and glucose-lowering drugs for coronary artery disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Intrepid™ TTVR System for tricuspid valve insufficiency | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| L-PSGB first for tachycardia, ventricular | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| L-PSGB first for ventricular fibrillation | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Laplace TTVR System for tricuspid valve insufficiency | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Left main stenting with intravascular lithotripsy for atherosclerosis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Left main stenting with intravascular lithotripsy for coronary artery disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Lepodisiran for atherosclerosis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Lepodisiran Sodium for atherosclerosis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Lorundrostat for hypertension | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| Lorundrostat 25mg+SGLT2i QD, Washout, Placebo+SGLT2i QD for hypertension | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| low dose CABG+iPSC-CMs for heart failure | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Low dose Jia Shen Tablet for heart failure | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| LuxValve PLlus for tricuspid valve insufficiency | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Mandibular advancement Device for essential hypertension | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Mandibular advancement Device for heart failure | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Mandibular advancement Device for hypertension | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Maridebart Cafraglutide for atherosclerosis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Medical or interventional therapy for rhythm control in atrial fibrillation (antiarrhythmic drugs, ablation, electric cardio version) for atrial fibrillation | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Medtronic Intrepid™ Transcatheter Tricuspid Valve Replacement (TTVR) System for tricuspid valve insufficiency | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Metformin ER for intermittent claudication | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Metformin hydrochloride for heart failure | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Midodrine for hypotension | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| MitraClip System for heart failure | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| MitraClip System for mitral valve insufficiency | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Muvalaplin for atherosclerosis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Narrative Intervention for Chronic Illness-Heart Failure for heart failure | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Neovasc Reducer for angina pectoris | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Nevibolol for microvascular angina | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Nicotine-Free Electronic Cigarette and behavioural change support. for cardiovascular diseases | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| NightWare for cardiovascular diseases | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Nintedanib for telangiectasia, hereditary hemorrhagic | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| NTLA-2001 for cardiomyopathies | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| obicetrapib 10 mg + ezetimibe 10 mg FDC daily for coronary artery disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Orforglipron for cardiovascular diseases | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Orforglipron for hypertension | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Pci for acute coronary syndrome | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| pharmacogenetic algorithm for atrial fibrillation | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo + Empagliflozin for heart failure | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Placebo + Lorundrostat for hypertension | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Placebo + Orforglipron for hypertension | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo QD + SGLT2i QD, Washout, Lorundrostat 25mg+SGLT2i QD for hypertension | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Polycap for atherosclerosis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| PolyCore (Polydextrin, L-Carnitine, D-xylitol) for heart failure | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| PolyPill for cardiovascular diseases | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| PolyPill for heart diseases | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| PolyPill for hypertension | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| PolyPill for non-st elevated myocardial infarction | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| PolyPill for st elevation myocardial infarction | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Polypill: Red Heart Pill for cardiovascular diseases | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Prasugrel for acute coronary syndrome | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Prasugrel or Ticagrelor for acute coronary syndrome | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Prasugrel or Ticagrelor for atrial fibrillation | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Qidan Xiaoke Granules + Standard Medical Therapy for coronary artery disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ranolazine for heart failure | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ranolazine for ventricular dysfunction, right | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Recombinant Human Thymosin Beta 4 Injection (NL005) for anterior wall myocardial infarction | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Recombinant Human Thymosin Beta 4 Injection (NL005) for st elevation myocardial infarction | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Recombinant varicella zoster virus glycoprotein e antigen for cardiovascular diseases | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Recombinant varicella zoster virus glycoprotein e antigen for myocardial infarction | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Red Heart Pill 2b (Polypill) for cardiovascular diseases | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Regadenoson for coronary artery disease | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Retatrutide for cardiovascular diseases | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Retatrutide for coronary artery disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Retatrutide for peripheral arterial disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Rivaroxaban for venous thromboembolism | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| RP-A501 for cardiomyopathy, hypertrophic | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| RP-A501 for hypertrophy, left ventricular | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Sacubitril-valsartan for heart failure | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| SAL0140 for hypertension | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Selnoflast for atherosclerosis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Semaglutide for atherosclerosis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Semaglutide for atrial fibrillation | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Silver diammine fluoride for heart arrest | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Sirolimus for arteriovenous malformations | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Sodium zirconium cyclosilicate for heart failure | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Tai Chi (CHI) for hypertension | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tai Chi (CHI) for prehypertension | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tenecteplase for st elevation myocardial infarction | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tertinat for atherosclerosis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tertinat for coronary artery disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Test group for hypertension | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Thiamine Mononitrate 300 mg for heart failure | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ticagrelor for acute coronary syndrome | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 19 |
| Ticagrelor for angina, stable | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ticagrelor for angina, unstable | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Ticagrelor for coronary artery disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 7 |
| Ticagrelor for myocardial infarction | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ticagrelor for non-st elevated myocardial infarction | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ticagrelor for st elevation myocardial infarction | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Ticagrelor + Aspirin for acute coronary syndrome | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ticagrelor + placebo for non-st elevated myocardial infarction | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ticagrelor + placebo for st elevation myocardial infarction | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tirzepatide for heart failure, systolic | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tirzepatide for hypertension | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| TNX-103 for heart failure | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Topaz TTVR System for tricuspid valve insufficiency | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Transcatheter PDA Coil for ductus arteriosus, patent | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Transcatheter tricuspid valve edge-to-edge repair for heart failure | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Transcatheter tricuspid valve edge-to-edge repair for tricuspid valve insufficiency | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Transcatheter Tricuspid Valve Intervention for tricuspid valve insufficiency | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Transcatheter tricuspid valve replacement for tricuspid valve insufficiency | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 6 |
| Transcatheter Tricuspid Valve Replacement (TTVR) with Laplace TTVR System for tricuspid valve insufficiency | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Transcatheter Tricuspid Valve Replacement (TTVR) with VDyne TriNova System for tricuspid valve insufficiency | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Transcatheter Tricuspid Valved Stent Graft for tricuspid valve insufficiency | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Transvenous Tricuspid Valve System implantation + OMT for tricuspid valve insufficiency | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| TRiCares Topaz TTVR System for tricuspid valve insufficiency | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tricuspid Valve Replacement System for tricuspid valve insufficiency | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tricuspid Valve Replacement System via jugular vein for tricuspid valve insufficiency | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| TricValve System for heart failure | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| trigagrelor for acute coronary syndrome | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Triple oral lipid lowering treatment for acute coronary syndrome | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| TruGamma System for tricuspid valve insufficiency | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Valsartan for heart failure | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| VDyne Transcatheter Tricuspid Valve Replacement System for tricuspid valve insufficiency | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Venous Excess Ultrasound (VEXUS)-Guided Management for hyperemia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Vericiguat for heart failure | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| VERVE-102 for atherosclerosis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| VERVE-102 for coronary artery disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| VERVE-102 for myocardial infarction | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Very-short DAPT less than 1 month after PCI for acute coronary syndrome | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Very-short DAPT less than 1 month after PCI for coronary artery disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Vicadrostat for hypertension | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| vicadrostat / empagliflozin combination 1 for heart failure | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| YMI024 for coronary artery disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ziltivekimab for atherosclerosis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Ziltivekimab for coronary artery disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ziltivekimab for myocardial infarction | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Zotarolimus-eluting stent (Endeavor Resolute) for coronary artery disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Zovegalisib for klippel-trenaunay-weber syndrome | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Zovegalisib for vascular malformations | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
Categories are from Medical Subject Headings (MeSH), U.S. National Library of Medicine, courtesy of the U.S. National Library of Medicine: MeSH. They may not reflect the most current data available from NLM. NLM does not endorse this site.